Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma
ACTIVE_NOT_RECRUITING
Status
Conditions
- Refractory HIV Associated Kaposi Sarcoma
Interventions
- DRUG: Dostarlimab in Combination Antiretroviral Therapy
Sponsor
Imperial College London